Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + etoposide + carboplatin for lung and mediastinal neuroendocrine tumors
ChiCTR2400085990Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib, etoposide and carboplatin in bronchial neuroendocrine tumor and thymic neuroendocrine carcinoma (TNEC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: pathological complete response. Started Jun 2024; status: recruiting.
02
Drugs
surufatinibetoposidecarboplatin
03
Conditions
bronchial neuroendocrine tumorthymic neuroendocrine carcinoma (TNEC)
Beyond the preview
Go deeper on ChiCTR2400085990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085990.